COOLEY DICKINSON HOSPITAL
1. Target Overview & Investment Thesis
COOLEY DICKINSON HOSPITAL is a 118-bed suburban community hospital in HAMPSHIRE, MA with $233.6M in net patient revenue and a 2.3% operating margin. The hospital serves a payer mix of 42.9% Medicare, 11.3% Medicaid, and 45.8% commercial.
Thesis: Undervalued. Our ML models identify $17.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 2.3% to 9.6% (+736bps).
| Net Revenue HCRIS | $233.6M |
| Current EBITDA COMPUTED | $5.3M |
| Operating Margin COMPUTED | 2.3% |
| Occupancy HCRIS | 61.4% |
| Revenue / Bed COMPUTED | $2.0M |
| Net-to-Gross HCRIS | 35.3% |
| Distress Probability ML | 47.4% |
2. Market Context & Competitive Position
MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of 2.3% places it above the state median. Among 56 size-comparable peers (59-236 beds), the median margin is -11.4%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (59-236), prioritizing same-state peers. 56 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| COOLEY DICKINSON HOSPITAL (Target) | MA | 118 | $233.6M | 2.3% |
| NEWTON WELLESLEY HOSPITAL | MA | 216 | $624.3M | -4.7% |
| SAINT VINCENT HOSPITAL | MA | 232 | $404.2M | 0.2% |
| CAMBRIDGE HEALTH ALLIANCE | MA | 225 | $383.9M | -50.0% |
| BETH ISRAEL DEACONESS - PLYMOU | MA | 150 | $349.1M | 2.6% |
| MOUNT AUBURN HOSPITAL | MA | 186 | $337.4M | -8.4% |
| STEWARD ST. ANNES HOSPITAL | MA | 175 | $322.3M | 12.8% |
| FAULKNER HOSPITAL | MA | 147 | $316.6M | -7.9% |
| EMERSON HOSPITAL | MA | 111 | $315.1M | -10.1% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $17.2M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $4.9M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $4.7M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $4.6M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.8M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $150K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $5.3M |
| + RCM Uplift | +$17.2M |
| Pro Forma EBITDA | $22.5M |
| Current Margin | 2.3% |
| Pro Forma Margin | 9.6% |
| WC Released (1x) | $9.0M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $8.2M | $207.1M | 25.29x | 90.8% |
| Base (11x exit) | 10.0x | 11.0x | $8.2M | $230.4M | 28.15x | 94.9% |
| Bull Case | 9.0x | 11.0x | $7.4M | $289.9M | 39.34x | 108.4% |
| Bull (12x exit) | 9.0x | 12.0x | $7.4M | $318.4M | 43.21x | 112.4% |
| Bear Case | 11.0x | 10.0x | $9.0M | $118.4M | 13.15x | 67.4% |
| Bear (11x exit) | 11.0x | 11.0x | $9.0M | $133.2M | 14.79x | 71.4% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Standard execution risk | RCM improvement requires management buy-in and 12-18 month implementation timeline |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 56 hospitals with 59-236 beds
- Same-state prioritization (n=57)
- Comp margins: P25=-18.6% / P50=-11.4% / P75=0.1%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.